Singapore, April 10, 2008: Dutch biotechnology company Crucell has announced a non-exclusive research license agreement with Korean biotech firm Celltrion for the production of recombinant proteins.

 

Under the agreement, Celltrion will evaluate Crucell’s Star technology for generating cell lines for the manufacture of biopharmaceuticals.

 

Star technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell’s PER C6 human cell technology and the widely used Chinese hamster ovary (CHO) cell line.